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Background: Rheumatoid Arthritis (RA) commonly affects the hands and wrists with inflammation, deformity,
pain, weakness and restricted mobility leading to reduced function. The effectiveness of exercise for RA hands is
uncertain, although evidence from small scale studies is promising. The Strengthening And Stretching for
Rheumatoid Arthritis of the Hand (SARAH) trial is a pragmatic, multi-centre randomised controlled trial evaluating
the clinical and cost effectiveness of adding an optimised exercise programme for hands and upper limbs to best
practice usual care for patients with RA.
Methods/design: 480 participants with problematic RA hands will be recruited through 17 NHS trusts. Treatments
will be provided by physiotherapists and occupational therapists. Participants will be individually randomised to
receive either best practice usual care (joint protection advice, general exercise advice, functional splinting and
assistive devices) or best practice usual care supplemented with an individualised exercise programme of
strengthening and stretching exercises. The study assessors will be blinded to treatment allocation and will follow
participants up at four and 12 months. The primary outcome measure is the Hand function subscale of the
Michigan Hand Outcome Questionnaire, and secondary outcomes include hand and wrist impairment measures,
quality of life, and resource use. Economic and qualitative studies will also be carried out in parallel.
Discussion: This paper describes the design and development of a trial protocol of a complex intervention study
based in therapy out-patient departments. The findings will provide evidence to support or refute the use of an
optimised exercise programme for RA of the hand in addition to best practice usual care.
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Rheumatoid arthritis (RA) is the most common inflam-
matory polyarthritis [1]. It is a chronic unpredictable
disorder that can cause persistent joint pain, joint dam-
age and long-term disability (especially in the hands and
feet). The prevalence of RA is 1.16% in women and
0.44% in men, increasing with age to 5% in those aged
over 55 [1]. Five years after diagnosis, 40% of people
with RA have relatively normal function (13% in remis-
sion), 44% have mild to moderate disability, and 16%
have marked functional disability [2]. Particular pro-
blems for the hands and wrists are inflammation, de-
formity, pain, weakness and restricted mobility resulting
in loss of function [3].
Although there is no cure for the disease, there are
increasingly effective drug treatments that can reduce
the impact of the disease, notably disease-modifying
anti-rheumatic drugs (DMARDs). The overall goals of
management are to prevent or control joint damage,
maximise function and decrease pain [4]. All current
UK clinical guidelines for the management of RA rec-
ommend the use of physiotherapy (PT) and occupa-
tional therapy (OT) as an adjunct to drug treatment
[5,6]. The three most common components of PT/OT
for RA hands are exercise therapy, joint protection ad-
vice and provision of functional splinting and assistive
devices [7].
A systematic review [8] of six randomized controlled
trials (RCTs) of the effectiveness of exercise programmes
in RA for the whole body concluded that dynamic exer-
cise (aerobic capacity and/or muscle strength training)
was effective in improving muscular endurance and
strength, without detrimental effects on disease activity
or pain. The number of RCTs that have specifically
investigated the effects of exercise on RA hands is li-
mited to five small studies (n=55,100, 67, 52 and 57
patients respectively) with mostly short term follow up
of a few months [9-13]. Each of these studies demon-
strated small improvements in hand strength or function
using exercise, with no increase in joint swelling, pain or
disease activity. The long term effectiveness of exercise
for RA hands has not been established.
The economic cost of RA is thought to be substantial
for both the individual patient and society as a whole
[4,14]. The highest costs are associated with those
patients that have poor and declining function early on
in their disease [15].
Aims
This paper describes the trial protocol of a large prag-
matic randomised controlled trial to evaluate the clin-
ical and cost effectiveness of adding an optimised
exercise programme for hands and upper limbs to best
practice usual care for patients with RA. An additionalaim is to describe, qualitatively, the experience of par-
ticipants with a particular emphasis on patient expect-
ation, exercise behaviours, and reasons for adherence/
non-adherence.Methods
Trial design
The SARAH trial is a pragmatic, multi-centre rando-
mised controlled trial (Figure 1).Participants
480 participants will be recruited from direct referrals
from Rheumatology clinics and from those referred to
PT/OT clinics. 17 NHS trusts in England will recruit
participants.
In addition to the recruitment of newly referred
patients, a number of the Rheumatology and some of
the PT/OT participating departments have a review
register of ‘chronic’ patients, periodically called in for re-
view appointments. Provided that these patients meet
the selection criteria described below, they will be
approached to participate in the trial.Selection criteria
All patients with Rheumatoid Arthritis meeting the
American College of Rheumatology clinical and im-
munological criteria [4], with pain and dysfunction of
the hands and/or wrist joints who are either not on a
disease modifying medication (DMARD), or who have
been on a stable DMARD regimen for three months or
more, will be included in the trial. Those fulfilling any of
the following criteria will be excluded:
i. Aged less than 18 years.
ii. Patients who have experienced upper limb joint
surgery, or fracture, in the previous six months.
iii. Patients on a waiting list for upper limb orthopaedic
surgery.
iv. Patients who are pregnant.
Patients will be asked to give written informed consent
according to principles of Good Clinical Practice and the
Declaration of Helsinki [16]. At the time of consent, out-
come assessors will collect baseline measures.Randomisation
Randomisation to the exercise programme or usual care
will be via a central telephone randomisation service at
Warwick Clinical Trials Unit, University of Warwick.
The randomisation schedule will be prepared by the trial
statistician (CM). Randomisation will be stratified by
centre using a variable block size.
Sample
RA patients referred from PT/OT and Rheumatology  clinics
Assessment for eligibility
Allocation
Individually randomised, stratified by site
Baseline assessments undertaken
n=480 
Best Practice Usual Care Arm
Joint protection, functional splinting and 
exercise advice
n=240
Follow-up Assessment 4 months
Primary and Secondary outcomes
Resource use
20% loss to follow-up/withdrawal
n=192
Follow-up Assessment 12 months
Primary and Secondary outcomes
Resource use
25% loss to follow-up/withdrawal
n=180
Intervention Arm
Usual Care and five sessions of exercise 
over 12 weeks
n=240
Follow-up Assessment 4 months
Primary and Secondary outcomes
Resource use
20% loss to follow-up/withdrawal 
n=192
Follow-up Assessment 12 months
Primary and Secondary outcomes
Resource use
25% loss to follow-up/withdrawal
n=180
Figure 1 Flowchart of study design.
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Eligibility checks will be performed, and consent for ran-
domisation taken. The research clinician will then tele-
phone the randomisation service, and only once the
patient is registered in the trial, will the random alloca-
tion be generated. Hence allocation will be concealed.
Blinding
The outcome assessor will be blind to the group alloca-
tion of the participant and will be independent of inter-
vention delivery. Participants will be requested not to
disclose group allocation to the outcome assessor. If an
outcome assessor is unblinded, this will be recorded. All
assessors will be asked to guess which allocation they
think the participant has been given at both follow-up
time points. The patients and therapists providing the
treatment cannot be blinded to the group allocation.Baseline assessment
After participants have been assessed for eligibility and
consent has been gained, baseline assessment will be
carried out. Questionnaires will be completed whilst the
outcome assessor conducts randomisation followed by a
physical assessment (both participant and assessor will
be unaware of allocation at this appointment). The base-
line measures are summarised in Table 1. A Research
Clinic Questionnaire will record demographic details
(age, sex, date of RA diagnosis, ethnicity, marital status,
hand dominance) and the Michigan Hand outcomes
Questionnaire (MHQ) [17], The MHQ has shown to be
a reliable, valid and responsive measure for an RA popu-
lation [18-20] and contains six domains (1) overall hand
function, (2) Activities of Daily Living (ADL), (3) pain,
(4) work performance, (5) aesthetics, and (6) patient sat-
isfaction. Scores range from 0 to 100, with higher scores
Table 1 Summary of measures to be collected
Domain Data source Measures – Instrument (Scale – high value is better score unless
specified)
Time
points
Function Research Clinic Questionnaire
(participant reported)
Michigan Hand Outcomes Questionnaire (MHQ)– overall Hand function score
(0–100)
0, 4, 12
Michigan Hand Outcomes Questionnaire (MHQ)– overall score (0–100)
Pain Research Clinic Questionnaire Pain sub-scale of MHQ (0–100; high score is worse) 0, 4, 12
‘Troublesomeness’ rating (0–20; high score is worse)
Impairment Research Clinic Examination
(performed by outcome assessor)
Joint deformity (MCPJ only) – goniometer (Degrees; high score is worse) 0, 4, 12
Wrist range of motion (flexion/extension) – goniometer (Degrees)
Finger range of motion (combined flexion and combined extension) – Ruler
(mm; high score is worse for combined flexion)
Thumb opposition range of motion - observation (0–10)
Dexterity - timed 9 hole peg test (Seconds; high score is worse)
Grip and Pinch Strength – dynamometer (Newtons)
Disease Activity Medical Records Research Clinic
Examination
Erythrocyte sedimentation rate (ESR – mm/h) and/or C-Reactive protein (CRP –
mg/l) blood test
0, 4, 12
Hand and wrist joint tenderness and swelling count – examination (0–22; high
score is worse)
Health-related
Quality of Life
Research Clinic Questionnaire SF-12(0-100) 0, 4, 12
EuroQol EQ-5D (health utility)(0–1)
Self-efficacy Research Clinic Questionnaire 7 item questionnaire 0, 4, 12
Satisfaction Research Clinic Questionnaire Treatment satisfaction item 4,12
Satisfaction sub-scale of MHQ (0–100)
Global Change Research Clinic Questionnaire Participant-rated global change question(7 point Likert scale) 4, 12
Adherence Research Clinic Questionnaire 5 item questionnaire 0, 4, 12
Economics Research Clinic Questionnaire Resource use questionnaire 4, 12
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For the pain scale, a higher score indicates more pain.
The questionnaire will also contain measures of pain
troublesomeness [21], self-efficacy [22], the EuroQol
EQ5D [23], the 12 item short form health survey (SF-12)
[24], health economics-related questions (employment
status, sick days in past month due to RA in wrists/
hands, benefits, highest educational qualification, house-
hold income) and treatment preference. Blood test
results (CRP, ESR, serum rheumatoid factor) and current
medication (prescribed and as required in last 7 days)
will be taken from hospital and prescription records.
The outcome assessor will be present to answer any
questions regarding the measures but will be trained not
to influence the participant’s responses.
Following completion of the case report form, a phys-
ical assessment will be performed in a standardised
order and standardised positions. This will include the
measurement of joint deformity (MCP ulnar/radial devi-
ation in maximum pronation, where ulnar deviation is
recorded as a positive value) and active range of motion
(wrist flexion and extension from the neutral position
with a goniometer [25], combined finger flexion accord-
ing to Ellis and Bruton [26], combined finger extension
and thumb opposition according to Kapandji [27]). Amodified swollen and tender joint count (22 joints of
hand and wrist [28]) will be taken, along with a test of
upper limb dexterity (Nine-hole peg test according to
Mathiowetz et al. [29]). Finally, two forms of grip
strength (full-hand and tripod pinch will be measured
using the MIE Digital Grip Analyser [30]. The standard
test position recommended by the American Society of
Hand Therapists will be used [31]. Patients will be sat in
a straight-backed chair without arm rests, feet flat on
floor, the shoulder of the assessed limb will be relaxed
by the side, the elbow flexed to 90 degrees, the wrist will
be extended and in ulnar deviation between 0 and 15
degrees and the forearm rotated to neutral pronation/
supination. The mean of three maximal three-second
grips will be calculated for each hand, with 60 second
rests between repetitions.
Interventions
The rationale and protocol for the interventions are
described in a separate paper [32]. All interventions are
delivered by PTs or OTs experienced in the treatment of
hand and rheumatology conditions. The therapists will
be independent of the recruitment and randomisation
procedures and will attend a training session by the trial
team and receive a training and reference manual as well
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vention to ensure quality standards are met. Therapists
will be permitted to deliver both the experimental and
control interventions, and each treatment session will be
recorded in a treatment log. Contamination will be mini-
mized through monitoring of treatment logs completed
at each session, quality assurance visits to each therapist
at the beginning of their time delivering interventions
on the trial and also limitation of additional therapy
materials (Patient exercise booklets, therapeutic putty,
Thera-bandW resistive band and hand exercisers) suffi-
cient to only cover participants randomised to theResearch Clin
Trial research clinician con
and performs ba
Best Practice Usual Care only
(control)
Assessment & Advice Session
4 and 12 
follow-
Randomisatio
Follow-up 1 (if required)
Follow-up 2 (if required)
Figure 2 Flowchart of interventions.experimental arm of the study. The aim is for all treat-
ments to be completed within four months of the base-
line assessment. Figure 2 provides an overview of the
interventions.
a. Control intervention – Best Practice Usual Care only
Participants randomised to the control intervention
will have between one and three sessions of outpatient
therapy with a maximum total contact time of one and a
half hours. Treatment will include the provision of joint
protection information, splinting, assistive devices andic Appointment
firms eligibility, consents 
seline assessment
Usual Care + Exercise
(experimental)
Assessment & Advice Session
Exercise Session 1
Exercise Session 5 and
discharge
month
up
n and referral
Exercise Session 2
Exercise Session 3
Exercise Session 4
Trial Team et al. BMC Musculoskeletal Disorders 2012, 13:230 Page 6 of 10
http://www.biomedcentral.com/1471-2474/13/230other general advice as required. The number of sessions
will depend on quantity of advice and education
required and/or for review of splinting/assistive devices.
This will be determined by the stage and severity of the
disease. The choice of treatments was made using two
principles; first, there is evidence that the treatments are
effective for hand dysfunction in RA [33], and second,
the treatments are consistent with current clinical guide-
lines [5,6]. Both control and experimental interventions
were developed using focus group meetings with stake
holder clinicians from across the UK.
b. Experimental intervention – Best Practice Usual Care
supplemented with an optimised exercise programme
Participants randomised to the exercise programme
will receive the usual care package plus an additional five
sessions with a therapist over a 12 week period. The aim
will be to increase hand function using exercises to
stretch and strengthen the muscles and tendons, as well
as mobilise the joints of the hand and wrist and improve
dexterity. This will be supported by a Home Exercise
Programme (reinforced by a behavioural activation ap-
proach and exercise diary) to be performed daily. This
number of contacts, spread over this period, allows
maximum progression of the intensity of exercise and
sufficient time for a physiological response in the
neuromuscular system to significantly improve function
[34]. The intervention will use a standardised protocol
of progression and, if necessary, regression of exercise
intensity. A modified Borg scale of perceived exertion
[35] will be used to regulate the intensity of resistance
exercise. The programme is based on the existing evi-
dence base, a professional consensus of UK PT/OTs
and a programme that has some evidence of short-
term effectiveness [36]. Adherence with the exercise
programme is vital to ensure the dosage required to
strengthen muscle and improve mobility is achieved.
Evidence based strategies to maximise adherence will
be incorporated into each treatment session, including
effective goal setting and action planning [37,38].
Treatment fidelity will be evaluated by recording con-
tent of sessions on treatment logs and the number of
sessions attended by participants in both arms of the
trial. Quality assurance checks will be made by the clin-
ical research fellow who will observe treatment sessions
for all therapists. We will also evaluate whether partici-
pants have progressed exercises within the exercise arm
using information from the treatment logs and exercise
diaries.
Other treatments
Participants may seek other forms of treatment during
the follow-up period. Additional treatments, includingcontacts with their GP or other health professional,
changes in types of medication, use of physical treat-
ments or alternative therapies, will be recorded as a
treatment outcome.
Follow-up data collection
Follow-up data collection will be by face-to-face clinical
assessment at four and 12 months. Where face-to-face
clinic assessment is not possible, postal and telephone
data collection methods will be used to obtain core data.
The outcome measures have been described in the base-
line assessment section and are detailed in Table 1.
The primary outcome measure will be the 12 month
Michigan Hand Outcome Questionnaire (MHQ) overall
hand function subscale score.
Sample size
A standardised mean effect size of 0.3 is reported to rep-
resent a clinically important difference in hand function
in this group [39]. A previous small study using a similar
intervention found a mean benefit of 0.7 in the AIMS2
with a standard deviation of 1.81 and a standardised ef-
fect size of 0.39 [36]. This suggests that in this larger,
more pragmatic multi-centre trial, a standardised effect
size of 0.3 in a similar function score of the MHQ is
realistic and meaningful. To show this difference with
80% power at the 5% significance level, we require data
on at least 352 participants (using SAS procedure
GLMPOWER). Assuming a worst case scenario of 25%
loss to follow-up, this would require 470 participants to
be recruited initially.
Over 15 months we expect 1,200 people with hand RA
to be referred to our participating centres. If half of
these are assessed for study entry and 80% of these join
the study, we will have 480 participants (1,200*0.5*0.8).
This is our target sample size (Figure 1). The assump-
tions underlying the sample size calculation will be mon-
itored by the Data Monitoring Committee.
Statistical analysis
Patients will be analysed in the treatment group to
which they were randomised, regardless of the treatment
that they actually received [40]. The trial will be reported
to CONSORT guidance and standards [41], and all
estimates will be reported 95% confidence intervals.
Demographic, clinical characteristics and baseline mea-
surements will be presented to compare the trial
groups and generalisability to clinical settings.
Primary outcome
The difference between the intervention and best prac-
tice usual care groups in mean MHQ overall hand func-
tion subscale score at 12 months will be analysed by a
linear model, adjusted for the baseline score. Adjustment
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by disease activity, medication and other patient charac-
teristics will be considered if there are imbalances be-
tween the intervention groups.
Secondary outcomes
Differences between groups for MHQ overall hand func-
tion score at 4 months, overall MHQ score at 4 and 12
months, measures of pain (sub-scale of MHQ and
‘troublesomeness’), impairment measures, self-efficacy,
joint counts, and quality of life (SF-12 and EQ-5D)
scores will be analysed in a similar manner to the pri-
mary outcome measure.
Analyses will also take account of baseline drug
regimens (no DMARD, single DMARD, combination
DMARD or biologic DMARD) and disease duration
(< or > 5 years since diagnosis). The impact of ther-
apist effects will be explored by including a random
therapist effect nested within centre in the various
models. The effect of missing data will be investi-
gated using multiple imputation analysis.
Complier-average causal effect (CACE) will be esti-
mated using an instrumental variable method [42].
Statistical analyses will be performed using SAS V9.2
software.
Economic evaluation
The economic analysis will include a ‘within-trial’ cost-
utility analysis, and modelling to estimate longer-term
costs and health effects if justified by the clinical results.
For the within-trial analysis, costs incurred and
Quality-Adjusted Life Years (QALYs) attained over the
twelve month study period will be estimated at the indi-
vidual patient level. The EuroQol (EQ-5D) will be used
to generate individuals’ utility scores at 0, 4 and 12
months (using the UK Social Tariff [43]), and QALYs
will then be calculated over this period using an area-
under-the-curve approach. Similarly, self-reported re-
source use data collected at 4 and 12 months will be
used to estimate individuals’ hand RA related health and
social care costs over the 12 month study period. The
cost of the exercise intervention will be estimated from
PT and OT records of time spent with patients, and of
any consumables used. Costs will be estimated from an
NHS and Personal Social Service perspective (as recom-
mended by NICE [44]), as well as from a broader soci-
etal perspective (including patient expenditure). Unit
costs for publicly funded services will be taken from
standard national sources [45], costs of private services
will be obtained directly from patients. As for clinical
outcomes, missing resource use and QALY data will be
estimated by multiple imputation.
A regression approach will then be used to estimate
between-group differences in mean costs and QALYs,adjusting for centre, sex, age and other baseline dif-
ferences between the study groups. An Incremental
Cost-Effectiveness Ratio (ICER), the additional cost per
additional QALY gained with the exercise programme
compared with best usual practice alone, will be calcu-
lated if appropriate. Interaction terms will also be used
to investigate possible treatment moderators and hence
to identify patient subgroups for whom treatment cost-
effectiveness is predictably different: age, sex, disease
activity, medication group, duration of disease, or other
relevant patient characteristics.
The twelve-month time horizon of the within-trial
analysis is quite limited. It is possible that extrapolation
of costs and QALYs beyond this time might lead to dif-
ferent conclusions about cost-effectiveness. For example,
if participants randomised to the exercise programme
had greater quality of life at twelve months than those
randomised to usual care alone, but that this health gain
came at a relatively high cost, then it is possible that fur-
ther accumulation of quality of life gains and/or cost
savings after the first year could bring the ICER below
the £20,000 to £30,000 per QALY gained threshold that
is usually considered to be cost-effective in the UK [46].
If so, we will use decision-analytic modelling with prob-
abilistic sensitivity analysis to extrapolate expected costs
and health effects.
Qualitative study
The qualitative study will help to provide a picture of
issues facing patients with hand problems as a result of
RA who participate in the experimental intervention
arm of the study. Semi-structured interviews will be
conducted by a researcher experienced in the design,
collection and analysis of qualitative data. Specific topics
covered will be living with RA, exercising with RA (in-
cluding adherence issues), and participant experience of
the SARAH trial.
We will interview enough participants to ensure we
are confident that theoretical sufficiency will be achieved
[47]. Therefore, we are aiming to interview up to 20 par-
ticipants randomised to receive the exercise interven-
tion. Sampling will be purposive to enable recruitment
of patients who report benefitting and not benefitting
from the exercise programme.
Interviews will be conducted following four and 12
month follow-up appointments either in hospitals or
patient homes. The development of the interview sched-
ule will be iterative and the questions asked may de-
velop and change as the interviews are conducted and
analysed [48].
All interviews will be recorded and then transcribed
for analysis. Interpretative Phenomenological Analysis
(IPA) will be used [49]. A feature of IPA is that the first
steps of analysis begin early in the research process with
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Initial analysis of each interview will be carried out as
soon after its completion as possible following the guide-
lines set out by Smith et al. [50].
One in five of the interviews will be coded independ-
ently by a 2nd member of the research team with experi-
ence of qualitative research (FT) to provide additional
knowledge by giving a different perspective on the coding
[51]. The research team will discuss the development of
themes as the research progresses, once again, with the
aim of providing a different perspective and enhancing
the development of themes. Participants will be given a
pseudonym to be used in any reports related to the study,
with the option to choose their own pseudonym.
Ethics committee approval
The SARAH trial was approved by the Oxford C Multi-
centre Research Ethics (MREC 08/H0606/47) Commit-
tee and by the Research and Development department
of each participating centre.
Discussion
Impairment and dysfunction of hands and upper limbs
are key concerns for patients with RA and optimal con-
servative management has yet to be defined and docu-
mented. This pragmatic randomised controlled trial
investigates whether there is additional benefit of an
optimised exercise programme for hands and upper
limbs when added to best practice usual care for this
group of patients.
A strength of this study is that the exercise
programme will be individually tailored to each patient,
reflecting clinical practice, and is designed to ensure a
sufficient dose of exercise is delivered. Strategies to
maximise adherence to the exercise programme are an
addition to an already promising intervention. The inter-
vention is designed to fit with the usual constraints of
NHS provision.
There is also methodological rigour in the design,
range of validated outcome measures and mixed meth-
ods utilised that will help to understand underlying
mechanisms and key patient perspectives. Long term
follow-up and the large sample size will allow for a com-
prehensive clinical effectiveness analysis. The parallel
health economics analysis will enable evaluation of cost-
effectiveness of treatments which are particularly pertin-
ent in the current economic climate.
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